Esomeprazole: a proton pump inhibitor

References

• Dent J, El Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut54(5), 710–717 (2005).
   PubMed Web of Science ®Google Scholar
• Spechler SJ. Epidemiology and natural history of GERD. Digestion51(Suppl. 1), 24–29 (1992).
   PubMed Web of Science ®Google Scholar
• Ho KY, Kang JY, Seow A. Prevalence of GI symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am. J. Gastroenterol.93(10), 1816–1822 (1998).
   PubMed Web of Science ®Google Scholar
• Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand. J. Gastroenterol.40(3), 302–311 (2005).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Petersen NJ, Carter J et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology126(7), 1692–1699 (2004).
   PubMed Web of Science ®Google Scholar
• Kutara JH . Ulcer epidemiology: an overview and proposed research framework. Gastroenterology96(Suppl. 2), 569–580 (1989).
   PubMed Web of Science ®Google Scholar
• Munnangi S, Sonnenberg A. Time trends of physician visits and treatment patterns of PUD in US. Arch. Intern. Med.157(13), 1489–1494 (1997).
   PubMed Web of Science ®Google Scholar
• Rosenstock SJ, Jørgensen T. Prevalence and incidence of PUD in a Danish county – a prospective cohort study. Gut36(6), 819–824 (1995).
   PubMed Web of Science ®Google Scholar
• Higham J, Kang J, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of hemorrhage among older subjects. Gut50(4), 460–464 (2002).
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am. J. Gastroenterol.101(9), 2128–2138 (2006).
   PubMed Web of Science ®Google Scholar
• Hassan-Alin M, Andersson T, Bredberg E, Röhss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. J. Clin. Pharmacol.56(9–10), 665–670 (2000).
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol. Ther.27(11), 1110–1121 (2008).
   PubMed Web of Science ®Google Scholar
• Lind T, Rydberg L, Kylebäck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther.14(7), 861–867 (2000).
   PubMed Web of Science ®Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, Röhss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharm.40(7), 523–537 (2001).
   Google Scholar
• Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin. Pharm.47(2), 75–89(2008).
   Google Scholar
• McCabe SM, Smith PF, Ma Q, Morse GD. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin. Drug Metab. Toxicol.3(2), 197–207 (2007).
   PubMed Web of Science ®Google Scholar
• Genta RM, Rindi G, Fiocca R, Magner DJ, D’Amico D, Levine DS. Effects of 6–12 months of esomeprazole treatment on the gastric mucosa. Am. J. Gastroenterol.98(6), 1257–1265 (2003).
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu. Rev. Pharmacol. Toxicol.35, 277–305 (1995).
   PubMed Web of Science ®Google Scholar
• Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci.47(5), 954–958 (2002).
   PubMed Web of Science ®Google Scholar
• Franco MT, Salvia G, Terrin G et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig. Liver Dis.32(8), 660–666 (2000).
   PubMedGoogle Scholar
• Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment. Pharmacol. Ther.14(6), 709–714 (2000).
   PubMed Web of Science ®Google Scholar
• Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion51(Suppl. 1), 59–67 (1992).
   PubMed Web of Science ®Google Scholar
• Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive esophagitis. Aliment. Pharmacol. Ther.25(5), 617–628 (2007).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion68(4), 184–188 (2003).
   PubMed Web of Science ®Google Scholar
• Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment. Pharmacol. Ther.18(7), 705–711(2003).
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am. J. Gastroenterol.98(12), 2616–2620 (2003)
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Katz PO, Chen YS, Sostek M, Pandolfino J, Kahrials PJ. Reanalysis of intragastric pH results based on updated correction factors for Slimline® and Zinetics™ 24 single-use pH catheters. Am. J. Gastroenterol.101(2), 404–405 (2006).
   PubMed Web of Science ®Google Scholar
• Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro oesophageal reflux symptoms. Eur. J. Clin. Pharmacol.60(8), 531–539 (2004).
   PubMed Web of Science ®Google Scholar
• Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease Dig. Dis. Sci.47(5), 954–958 (2002).
   PubMed Web of Science ®Google Scholar
• Katz PO, Koch FK, Ballard ED et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment. Pharmacol. Ther.25(2), 197–205 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Miner PB Jr, Schlesinger PK, Liu S, Silberg DG. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment. Pharmacol. Ther.23(8), 1189–1196 (2006).
   PubMed Web of Science ®Google Scholar
• Klinkenberg-Knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology118(4), 661–669 (2000).
   PubMed Web of Science ®Google Scholar
• Miehlke S, Madisch A, Kirsch C et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. Aliment. Pharmacol. Ther.21(8), 963–967 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson DA, Stacy T, Ryan M et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther.22(2), 129–134 (2005).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith C, Backlund A, Eckerwall G, Lind T, Fjellman M, Röhss K. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose–response study. Clin. Drug Invest.28(6), 333–343 (2008).
   PubMed Web of Science ®Google Scholar
• Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology39(4), 322–324 (1992).
   PubMedGoogle Scholar
• Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin. Drug Invest.24(1), 1–7 (2004).
   PubMed Web of Science ®Google Scholar
• Metz DC. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion62, 73–81 (2005).
   Google Scholar
• Wilder-Smith CH, Bondarov P, Lundgren M et al. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur. J. Gastroenterol. Hepatol.17(2), 191–197 (2005).
   PubMed Web of Science ®Google Scholar
• Metz DC, Miner PB, Heuman DM et al. Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther.22(9), 813–821 (2005).
   PubMed Web of Science ®Google Scholar
• Pisegna JR, Sostek MB, Monyak JT, Miner PB Jr. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. Aliment. Pharmacol. Ther.27(6), 483–490 (2008).
   PubMed Web of Science ®Google Scholar
• Röhss K, Wilder-Smith C, Kilhamn J, Fjellman M, Lind T. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects. Int. J. Clin. Pharmacol. Ther.45(6), 345–354 (2007).
   PubMed Web of Science ®Google Scholar
• Hartmann D, Eickhoff A, Damian U, Riemann JF, Schilling D. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. Eur. J. Gastroenterol. Hepatol.19(2), 133–137 (2007).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Röhss K, Bondarov P, Hallerbäck B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment. Pharmacol. Ther.20(10), 1099–1104 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider H, Van Rensburg C, Schmidt S et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion70(4), 250–256 (2004).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith C, Röhss K, Bondarov P et al. Intravenous esomeprazole 40mg is effective for the control of intragastric acid levels whether given as a 3-minute injection or a 30-minute infusion. Clin. Drug Invest.25(8), 517–525 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson DA, Orr WC, Crawley JA et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am. J. Gastroenterol.100(9), 1914–1922 (2005).
   PubMed Web of Science ®Google Scholar
• Armstrong D, Talley NJ, Lauritsen K et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment. Pharmacol. Ther.20(4), 413–421 (2004).
   PubMed Web of Science ®Google Scholar
• Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs. esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J. Gastroenterol.11(20), 3091–3098 (2005).
   PubMed Web of Science ®Google Scholar
• Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am. J. Gastroenterol.103(2), 267–275 (2008).
   PubMed Web of Science ®Google Scholar
• Reichel O, Dressel H, Wiederänders K, Issing WJ. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol. Head Neck Surg.139(3), 414–420 (2008).
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Richter JE, Stasney CR et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope116(2), 254–260 (2006).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Jones RH, Yeomans ND et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther.25(7), 813–821 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkey C, Talley NJ, Yeomans ND et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am. J. Gastroenterol.100(5), 1028–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Hawkey C, Talley NJ, Scheiman J et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res. Ther.9(1), R17 (2007).
   PubMed Web of Science ®Google Scholar
• DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol.94(6), 1434–1442 (1999).
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Lauritsen K et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment. Pharmacol. Ther.21(6), 739–746 (2005).
   PubMed Web of Science ®Google Scholar
• Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment. Pharmacol. Ther.18(6), 587–594 (2003).
   PubMed Web of Science ®Google Scholar
• Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig. Dis. Sci.51(5), 844–850 (2006).
   PubMed Web of Science ®Google Scholar
• Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am. J. Gastroenterol.96(3), 656–665 (2001).
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol. Ther.14(10), 1249–1258 (2001).
   Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. J. Gastroenterol.97(3), 575–583 (2002).
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin. Gastroenterol. Hepatol.4(12), 1452–1458 (2006).
   PubMed Web of Science ®Google Scholar
• Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology95(4), 903–912 (1988).
   PubMed Web of Science ®Google Scholar
• Vigneri S, Termini R, Leandro G et al. A comparison of give maintenance therapies for reflux esophagitis. N. Engl. J. Med.333(17), 1106–1110 (1995).
   PubMed Web of Science ®Google Scholar
• Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology95(4), 903–912 (1988).
   PubMed Web of Science ®Google Scholar
• Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin. Gastroenterol. Hepatol.4(7), 852–859 (2006).
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Deviere J, Bigard MA et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment. Pharmacol. Ther.17(3), 333–341 (2003).
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Lauritsen K et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment. Pharmacol. Ther.22(9), 803–811 (2005).
   PubMed Web of Science ®Google Scholar
• Sjöstedt S, Befrits R, Sylvan A et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment. Pharmacol. Ther.22(3), 183–191 (2005).
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA272 (1), 65–69 (1994).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut.56(6), 772–781 (2007).
   PubMed Web of Science ®Google Scholar
• Marshall BJ, Goodwin CS, Warren JR et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet2(8626–8627), 1437–1442 (1988).
   PubMed Web of Science ®Google Scholar
• Chiorean MV, Locke GR 3rd, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am. J. Gastroenterol.97(12), 3015–3022 (2002).
   PubMed Web of Science ®Google Scholar
• Tulassay Z, Stolte M, Sjolund M et al. Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur. J. Gastroenterol. Hepatol.20(6), 526–536 (2008).
   PubMed Web of Science ®Google Scholar
• Tulassay Z, Kryszewski A, Dite P et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur. J. Gastroenterol. Hepatol.13(12), 1457–1465 (2001).
   PubMed Web of Science ®Google Scholar
• Subei IM, Cardona HJ, Bachelet E et al. One week of esomeprazole triple therapy vs. 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healing in Helicobacter pylori-positive patients. Dig. Dis. Sci.52(6), 1505–1512 (2007).
   PubMed Web of Science ®Google Scholar
• Wang X, Fang JY, Lu R, Sun DF. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion73(2–3), 178–186 (2006).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig. Liver Dis.36(4), 253–259 (2004).
   PubMedGoogle Scholar
• Goldstein JL, Johanson JF, Hawkey CJ, Suchower LJ, Brown KA. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole. Aliment. Pharmacol. Ther.26(8), 1101–1111 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Johanson JF, Suchower LJ et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am. J. Gastroenterol.100(12), 2650–2657 (2005).
   PubMed Web of Science ®Google Scholar
• Lai KC, Chu KM, Hui WM et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin. Gastroenterol. Hepatol.4(7), 860–865 (2006).
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol.101(4), 701–710 (2006).
   PubMed Web of Science ®Google Scholar
• Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol.103(10), 2465–2473 (2008).
   PubMed Web of Science ®Google Scholar
• Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger–Ellison syndrome or idiopathic gastric acid hypersecretion. Am. J. Gastroenterol.102(12), 2648–2654 (2007).
   PubMed Web of Science ®Google Scholar
• Nexium®, prescribing information. AstraZeneca, London, UK (2001).
   Google Scholar
• Sjövall H, Björnsson E, Holmberg J, Hasselgren G, Röhss K, Hassan-Alin M. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur. J. Gastroenterol. Hepatol.14(5), 491–496 (2002).
   PubMed Web of Science ®Google Scholar
• Gold BD, Gunasekaran T, Tolia V et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr.45(5), 520–529 (2007).
   PubMed Web of Science ®Google Scholar
• Li J, Zhao J, Hamer-Maansson JE, Andersson T et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin. Ther.28(3), 419–427 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao J, Li J, Hamer-Maansson JE et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin. Ther.28(11), 1868–1876 (2006).
   PubMed Web of Science ®Google Scholar
• Hasselgren G, Hassan-Alin M, Andersson T, Claar-Nilsson C, Röhss K. Pharmacokinetic study of esomeprazole in the elderly. Clin. Pharm.40(2), 145–150 (2001).
   Google Scholar
• Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig. Dis. Sci.47(7), 1526–1529 (2002).
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Arnon J, Shechtman S et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment. Pharmacol. Ther.21(3), 269–275 (2005).
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA296(24), 2947–2953 (2006)
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif. Tissue Int.79(2), 76–83 (2006)
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy28(8), 951–959 (2008).
   PubMed Web of Science ®Google Scholar
• Zaidi M. Modularity of osteoclast behaviour and “mode-specific” inhibition of osteoclast function. Biosci. Rep.10(6), 547–556 (1990).
   PubMed Web of Science ®Google Scholar
• Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA294(23), 2989–2995 (2005).
   PubMed Web of Science ®Google Scholar
• Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ175(7), 745–748 (2006).
   PubMed Web of Science ®Google Scholar
• Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis.41(9), 1254–1260 (2005).
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Stamm WE, Mulligan ME. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect. Immun.59(7), 2456–2462 (1991).
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA292(16), 1955–1960 (2004).
   PubMed Web of Science ®Google Scholar
• Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf.31(7), 627–636 (2008).
   PubMed Web of Science ®Google Scholar
• Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J. Clin. Gastroenterol.30(1), 29–33 (2000).
   PubMed Web of Science ®Google Scholar
• O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am. J. Med.118(7), 778–781 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart CA, Termanini B, Sutliff VE et al. Iron absorption in patients with Zollinger–Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment. Pharmacol. Ther.12(1), 83–98 (1998).
   PubMed Web of Science ®Google Scholar
• Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med. J.97(9), 887–889 (2004).
   PubMed Web of Science ®Google Scholar